251 related articles for article (PubMed ID: 7693420)
1. Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 x 6 cycles vs FEC 50 x 3 cycles vs FEC 75 x 3 cycles. The French Adjuvant Study Group.
Fumoleau P; Devaux Y; Vo Van ML; Kerbrat P; Fargeot P; Schraub S; Mihura J; Namer M; Mercier M
Drugs; 1993; 45 Suppl 2():38-45. PubMed ID: 7693420
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
Fumoleau P; Kerbrat P; Romestaing P; Fargeot P; Brémond A; Namer M; Schraub S; Goudier MJ; Mihura J; Monnier A; Clavère P; Serin D; Seffert P; Pourny C; Facchini T; Jacquin JP; Sztermer JF; Datchary J; Ramos R; Luporsi E
J Clin Oncol; 2003 Jan; 21(2):298-305. PubMed ID: 12525522
[TBL] [Abstract][Full Text] [Related]
3. Postmenopausal patients with node-positive resectable breast cancer. Tamoxifen vs FEC 50 (6 cycles) vs FEC 50 (6 cycles) plus tamoxifen vs control--preliminary results of a 4-arm randomised trial. The French Adjuvant Study Group.
Gérard JP; Héry M; Gedouin D; Monnier A; Goudier MJ; Jacquin JP; Plat F; Cabarrot E; Serin D; Namer M
Drugs; 1993; 45 Suppl 2():60-7. PubMed ID: 7693424
[TBL] [Abstract][Full Text] [Related]
4. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.
French Adjuvant Study Group
J Clin Oncol; 2001 Feb; 19(3):602-11. PubMed ID: 11157009
[TBL] [Abstract][Full Text] [Related]
5. Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer. A trial of the International Collaborative Cancer Group (ICCG).
Wils J; Coombes RC; Marty M; Bliss J; Woods E
Drugs; 1993; 45 Suppl 2():46-50; discussion 49-50. PubMed ID: 7693422
[TBL] [Abstract][Full Text] [Related]
6. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I
J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257
[TBL] [Abstract][Full Text] [Related]
7. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Del Mastro L; De Placido S; Bruzzi P; De Laurentiis M; Boni C; Cavazzini G; Durando A; Turletti A; Nisticò C; Valle E; Garrone O; Puglisi F; Montemurro F; Barni S; Ardizzoni A; Gamucci T; Colantuoni G; Giuliano M; Gravina A; Papaldo P; Bighin C; Bisagni G; Forestieri V; Cognetti F;
Lancet; 2015 May; 385(9980):1863-72. PubMed ID: 25740286
[TBL] [Abstract][Full Text] [Related]
8. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
Bergh J; Wiklund T; Erikstein B; Lidbrink E; Lindman H; Malmström P; Kellokumpu-Lehtinen P; Bengtsson NO; Söderlund G; Anker G; Wist E; Ottosson S; Salminen E; Ljungman P; Holte H; Nilsson J; Blomqvist C; Wilking N
Lancet; 2000 Oct; 356(9239):1384-91. PubMed ID: 11052580
[TBL] [Abstract][Full Text] [Related]
9. A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group.
J Clin Oncol; 1991 Feb; 9(2):305-12. PubMed ID: 1988577
[TBL] [Abstract][Full Text] [Related]
10. Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106).
Kerbrat P; Desmoulins I; Roca L; Levy C; Lortholary A; Marre A; Delva R; Rios M; Viens P; Brain É; Serin D; Edel M; Debled M; Campone M; Mourret-Reynier MA; Bachelot T; Foucher-Goudier MJ; Asselain B; Lemonnier J; Martin AL; Roché H
Eur J Cancer; 2017 Jul; 79():166-175. PubMed ID: 28501763
[TBL] [Abstract][Full Text] [Related]
11. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Roché H; Fumoleau P; Spielmann M; Canon JL; Delozier T; Serin D; Symann M; Kerbrat P; Soulié P; Eichler F; Viens P; Monnier A; Vindevoghel A; Campone M; Goudier MJ; Bonneterre J; Ferrero JM; Martin AL; Genève J; Asselain B
J Clin Oncol; 2006 Dec; 24(36):5664-71. PubMed ID: 17116941
[TBL] [Abstract][Full Text] [Related]
12. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment.
French Epirubicin Study Group
J Clin Oncol; 2000 Sep; 18(17):3115-24. PubMed ID: 10963640
[TBL] [Abstract][Full Text] [Related]
13. Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group.
Brufman G; Colajori E; Ghilezan N; Lassus M; Martoni A; Perevodchikova N; Tosello C; Viaro D; Zielinski C
Ann Oncol; 1997 Feb; 8(2):155-62. PubMed ID: 9093724
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
Veyret C; Levy C; Chollet P; Merrouche Y; Roche H; Kerbrat P; Fumoleau P; Fargeot P; Clavere P; Chevallier B
Cancer; 2006 Dec; 107(11):2535-44. PubMed ID: 17054108
[TBL] [Abstract][Full Text] [Related]
15. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
Martín M; Ruiz Simón A; Ruiz Borrego M; Ribelles N; Rodríguez-Lescure Á; Muñoz-Mateu M; González S; Margelí Vila M; Barnadas A; Ramos M; Del Barco Berron S; Jara C; Calvo L; Martínez-Jáñez N; Mendiola Fernández C; Rodríguez CA; Martínez de Dueñas E; Andrés R; Plazaola A; de la Haba-Rodríguez J; López-Vega JM; Adrover E; Ballesteros AI; Santaballa A; Sánchez-Rovira P; Baena-Cañada JM; Casas M; del Carmen Cámara M; Carrasco EM; Lluch A
J Clin Oncol; 2015 Nov; 33(32):3788-95. PubMed ID: 26416999
[TBL] [Abstract][Full Text] [Related]
16. A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil-epirubicine-cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000).
Delbaldo C; Serin D; Mousseau M; Greget S; Audhuy B; Priou F; Berdah JF; Teissier E; Laplaige P; Zelek L; Quinaux E; Buyse M; Piedbois P;
Eur J Cancer; 2014 Jan; 50(1):23-30. PubMed ID: 24183460
[TBL] [Abstract][Full Text] [Related]
17. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial.
Bonneterre J; Roché H; Kerbrat P; Brémond A; Fumoleau P; Namer M; Goudier MJ; Schraub S; Fargeot P; Chapelle-Marcillac I
J Clin Oncol; 2005 Apr; 23(12):2686-93. PubMed ID: 15837983
[TBL] [Abstract][Full Text] [Related]
18. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.
Ottosson S; Magnusson K; Hultborn R
Anticancer Res; 1999; 19(5C):4429-34. PubMed ID: 10650787
[TBL] [Abstract][Full Text] [Related]
19. FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results.
Pacini P; Rinaldini M; Algeri R; Guarneri A; Tucci E; Barsanti G; Neri B; Bastiani P; Marzano S; Fallai C
Eur J Cancer; 2000 May; 36(8):966-75. PubMed ID: 10885599
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
Levine MN; Bramwell VH; Pritchard KI; Norris BD; Shepherd LE; Abu-Zahra H; Findlay B; Warr D; Bowman D; Myles J; Arnold A; Vandenberg T; MacKenzie R; Robert J; Ottaway J; Burnell M; Williams CK; Tu D
J Clin Oncol; 1998 Aug; 16(8):2651-8. PubMed ID: 9704715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]